Zobrazeno 1 - 10
of 186
pro vyhledávání: '"Hira Rizvi"'
Autor:
Yuan Chen, Biagio Ricciuti, Matthew D Hellmann, Hira Rizvi, Mark M Awad, Giuseppe Lamberti, Arielle Elkrief, Jamie E Chaft, Xinan Wang, Samantha Brown, Charles M Rudin, Joao M Victor Alessi, Isabel R Preeshagul, Federica Pecci, Alessandro Di Federico, Jacklynn V Egger, Gregory J Riely, Mark G Kris, Marc Ladanyi, Ronglai Shen, Adam J Schoenfeld
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Single-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) is approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression ≥1%. These regimens have not bee
Externí odkaz:
https://doaj.org/article/1db67c48820e42a9b021621d9022be62
Autor:
Jia Luo, Hira Rizvi, Margaret Callahan, Jason Beattie, Paige Fuentes, Adam Schoenfeld, I-Hsin Lin, Neil J Shah, Mohit Chawla
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background Pneumonitis related to immune checkpoint blockade is uncommon but can be severe, fatal or chronic. Steroids are first-line treatment, however, some patients are refractory or become resistant to steroids. Like many immune-related adverse e
Externí odkaz:
https://doaj.org/article/ebc425dd56e54588bcc8ddd9f3fb4c5b
Autor:
Michael Green, Dmitriy Zamarin, Katherine Panageas, Taha Merghoub, Weiping Zou, Cailian Liu, Jedd Wolchok, Matthew Hellmann, Joseph Chan, Hongyu Shi, Hira Rizvi, Jessica Waninger, Aditi Gupta, Nicholas Ceglia, Viola Allaj, Giulia Zago, Nisarg Shah, Sai Sharma, Marissa Mattar, Yonina Bykov, Corrin Wohlhieter, Fathema Uddin, Inna Khodos, Angel Qin, Vinod Balachandran, Sohrab Shah, Andrew McPherson, Jason Lewis, Justin Perry, Elisa de Stanchina, Triparna Sen, John Poirier, Charles Rudin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/40d967b30569450689026463a728aa99
Autor:
Mehmet Altan, Fangxin Hong, John V Heymach, Elizabeth Jiménez-Aguilar, Zihan Wei, Andrew J Plodkowski, Peter Sawan, Jia Luo, Hira Rizvi, Brett W Carter
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Externí odkaz:
https://doaj.org/article/648bd296fa33492987d617a398d69e86
Autor:
Mehmet Altan, Fangxin Hong, John V Heymach, Elizabeth Jiménez-Aguilar, Zihan Wei, Andrew J Plodkowski, Peter Sawan, Jia Luo, Hira Rizvi, Brett W Carter
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Patients with non–small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from phase III immunotherapy clinical trials. We sought to evaluate clinical outcomes to first
Externí odkaz:
https://doaj.org/article/ce27967cc8bd43ab8337e6a4dcfb90a4
Autor:
Madhuri Martin, Joshua K. Sabari, Gulisa Turashvili, Darragh F. Halpenny, Hira Rizvi, Natalie Shapnik, Vicky Makker
Publikováno v:
Gynecologic Oncology Reports, Vol 24, Iss , Pp 94-98 (2018)
Introduction: Multiple primary tumors (MPTs) are defined as two or more separate synchronous or metachronous neoplasms occurring in different sites in the same individual. These tumors differ in histology, as well as primary sites from which they ari
Externí odkaz:
https://doaj.org/article/6e70fb5073294f24a54a2fa8f20d3a78
Autor:
Arvind Ravi, Matthew D. Hellmann, Monica B. Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T. Griffin, Natalie I. Vokes, Mustafa Sakhi, Vashine Kamesan, Hira Rizvi, Biagio Ricciuti, Patrick M. Forde, Valsamo Anagnostou, Jonathan W. Riess, Don L. Gibbons, Nathan A. Pennell, Vamsidhar Velcheti, Subba R. Digumarthy, Mari Mino-Kenudson, Andrea Califano, John V. Heymach, Roy S. Herbst, Julie R. Brahmer, Kurt A. Schalper, Victor E. Velculescu, Brian S. Henick, Naiyer Rizvi, Pasi A. Jänne, Mark M. Awad, Andrew Chow, Benjamin D. Greenbaum, Marta Luksza, Alice T. Shaw, Jedd Wolchok, Nir Hacohen, Gad Getz, Justin F. Gainor
Publikováno v:
Nature Genetics. 55:807-819
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first jo
Autor:
Noura J. Choudhury, Jessica A. Lavery, Samantha Brown, Ino de Bruijn, Justin Jee, Thinh Ngoc. Tran, Hira Rizvi, Kathryn C. Arbour, Karissa Whiting, Ronglai Shen, Matthew Hellmann, Philippe L. Bedard, Celeste Yu, Natasha Leighl, Michele LeNoue-Newton, Christine Micheel, Jeremy L. Warner, Michelle S. Ginsberg, Andrew Plodkowski, Jeffrey Girshman, Peter Sawan, Shirin Pillai, Shawn M. Sweeney, Kenneth L. Kehl, Katherine S. Panageas, Nikolaus Schultz, Deb Schrag, Gregory J. Riely
Publikováno v:
Clinical Cancer Research.
Purpose: We describe the clinical and genomic landscape of the non-small cell lung cancer (NSCLC) cohort of the AACR Project GENIE Biopharma Collaborative (BPC). Experimental Design: 1,846 patients with NSCLC whose tumors were sequenced from 2014 to
Autor:
Joao V. Alessi, Xinan Wang, Arielle Elkrief, Biagio Ricciuti, Yvonne Y. Li, Hersh Gupta, Liam F. Spurr, Hira Rizvi, Jia Luo, Federica Pecci, Giuseppe Lamberti, Gonzalo Recondo, Deepti Venkatraman, Alessandro Di Federico, Malini M. Gandhi, Victor R. Vaz, Mizuki Nishino, Lynette M. Sholl, Andrew D. Cherniack, Marc Ladanyi, Adam Price, Allison L. Richards, Mark Donoghue, James Lindsay, Bijaya Sharma, Madison M. Turner, Kathleen L. Pfaff, Kristen D. Felt, Scott J. Rodig, Xihong Lin, Matthew L. Meyerson, Bruce E. Johnson, David C. Christiani, Adam J. Schoenfeld, Mark M. Awad
Publikováno v:
Journal of Thoracic Oncology.
Autor:
Rami S, Vanguri, Jia, Luo, Andrew T, Aukerman, Jacklynn V, Egger, Christopher J, Fong, Natally, Horvat, Andrew, Pagano, Jose de Arimateia Batista, Araujo-Filho, Luke, Geneslaw, Hira, Rizvi, Ramon, Sosa, Kevin M, Boehm, Soo-Ryum, Yang, Francis M, Bodd, Katia, Ventura, Travis J, Hollmann, Michelle S, Ginsberg, Jianjiong, Gao, Matthew D, Hellmann, Jennifer L, Sauter, Rami, Vanguri
Publikováno v:
Nature Cancer. 3:1151-1164
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer (NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we show the predictive capacity of integrating medical imaging, histopath